A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, Solnes L, Abramson V, Carey L, Rimawi M, Specht J, Storniolo A, Vaklavas C, Krop I, Winer E, Denbow R, Valero V, Wolff A, Wahl R, Huang C, Stearns V, Thompson E, Connolly R. A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). The Breast 2025, 81: 104432. PMID: 40049115, PMCID: PMC11928837, DOI: 10.1016/j.breast.2025.104432.Peer-Reviewed Original ResearchTissue-based biomarkersBreast cancerHER2-positive breast cancerHER2 3+Negative predictive valueEarly metabolic changesNeoadjuvant pertuzumabScore cut-offNeoadjuvant therapyIntrinsic subtypesSULmaxC1D15PET/CTDays post-initiationHER2 proteinYouden indexComposite biomarkerDe-intensificationHER2Post-initiationPredictive valueBiomarker performanceC-statisticImaging biomarkersMetabolic changes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply